August 23, 2010
Treatment Options of Non-Constipation Irritable Bowel Syndrome Announced Salix Announces FDA Acceptance for Filing and Priority Review Designation For XIFAXAN550 sNDA For the Treatment of Non-Constipation Irritable Bowel Syndrome PDUFA Action Date Designated as December 7, 2010 RALEIGH, N.C., Aug 09, 2010 (BUSINESS WIRE) — Salix Pharmaceuticals, Ltd. /quotes/comstock/15*!slxp/quotes/nls/slxp (SLXP 40.42, +0.22, +0.55%) today announced [...]
Read the full article →
August 10, 2010
FDA accepts Salix’s XIFAXAN550 sNDA for Priority Review Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company’s efficacy supplement to the New Drug Application (NDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and [...]
Read the full article →